Donna M. Huryn

Donna M. Huryn

Auto-generated profile, based on publicly available information

Donna M. Huryn

Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19194, United States

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2013 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
CBCarlo Ballatore
Carlo Ballatore
DHDonna M. Huryn
Donna M. Huryn
ASAmos B. Smith
Amos B. Smith

1 December 1992 in Chemical Reviews
Verified
Journal Article
Closed access
DHDonna M. Huryn
Donna M. Huryn
MOMasami Okabe
Masami Okabe

19 February 2016 in Science
Verified
Journal Article
Closed access
PDF file
SBSoojay Banerjee
Soojay Banerjee
ABAlberto Bartesaghi
Alberto Bartesaghi
AMAlan Merk
Alan Merk
PRPrashant Rao
Prashant Rao
SBStacie L. Bulfer
Stacie L. Bulfer
SSSriram Subramaniam
Sriram Subramaniam
AAA ATPase conformational high jinks: The protein p97 is an AAA adenosine triphosphatase (ATPase) that uses energy from ATP hydrolysis to regulate substrates involved in intracellular protein quality control. Its role in this central process makes it a target for cancer chemotherapy. Banerjee et al. used cryo-electron microscopy to determine high-resolution structures for multiple conformational states of this dynamic macromolecular machine. They also determined the structure of the ADP-bound state bound to an inhibitor. The structures give insight into nucleotide-driven structural changes that drive function and show how inhibitor binding prevents these conformational changes Science , this issue p. 871

30 March 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
PLPierrik Lassalas
Pierrik Lassalas
BGBryant Gay
Bryant Gay
CLCaroline Lasfargeas
Caroline Lasfargeas
MJMichael J. James
Michael J. James
VTVan Tran
Van Tran
CBCarlo Ballatore
Carlo Ballatore
The replacement of a carboxylic acid with a surrogate structure, or (bio)-isostere, is a classical strategy in medicinal chemistry. The general underlying principle is that by maintaining the features of the carboxylic acid critical for biological activity, but appropriately modifying the physicochemical properties, improved analogs may result. In this context, a systematic assessment of the physicochemical properties of carboxylic acid isosteres would be desirable to enable more informed decisions of potential replacements to be used for analog design. Herein we report the structure–property relationships (SPR) of 35 phenylpropionic acid derivatives, in which the carboxylic acid moiety is replaced with a series of known isosteres. The data set generated provides an assessment of the relative impact on the physicochemical properties that these replacements may have compared to the carboxylic acid analog. As such, this study presents a framework for how to rationally apply isosteric replacements of the carboxylic acid functional group.

28 September 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CBCarlo Ballatore
Carlo Ballatore
KBKurt R. Brunden
Kurt R. Brunden
DHDonna M. Huryn
Donna M. Huryn
JTJohn Q. Trojanowski
John Q. Trojanowski
VLVirginia M.-Y. Lee
Virginia M.-Y. Lee
AIAmos B Smith III
Amos B Smith III

1 April 2019 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
MCM. Grazia Cotticelli
M. Grazia Cotticelli
SXShujuan Xia
Shujuan Xia
DLDaniel Lin
Daniel Lin
TLTaehee Lee
Taehee Lee
LTLeila Terrab
Leila Terrab
RWRobert B Wilson
Robert B Wilson
Friedreich ataxia (FRDA) is a progressive neuro- and cardio-degenerative disorder characterized by ataxia, sensory loss, and hypertrophic cardiomyopathy. In most cases, the disorder is caused by GAA repeat expansions in the first introns of both alleles of the FXN gene, resulting in decreased expression of the encoded protein, frataxin. Frataxin localizes to the mitochondrial matrix and is required for iron-sulfur-cluster biosynthesis. Decreased expression of frataxin is associated with mitochondrial dysfunction, mitochondrial iron accumulation, and increased oxidative stress. Ferropotosis is a recently identified pathway of regulated, iron-dependent cell death, which is biochemically distinct from apoptosis. We evaluated whether there is evidence for ferroptotic pathway activation in cellular models of FRDA. We found that primary patient-derived fibroblasts, murine fibroblasts with FRDA-associated mutations, and murine fibroblasts in which a repeat expansion had been introduced (KIKO) were more sensitive than normal control cells to erastin, a known ferroptosis inducer. We also found that the ferroptosis inhibitors SRS11-92 and Fer-1, used at 500 nM, were efficacious in protecting human and mouse cellular models of FRDA treated with ferric ammonium citrate (FAC) and an inhibitor of glutathione synthesis (BSO), whereas caspase-3 inhibitors failed to show significant biological activity. Cells treated with FAC and BSO consistently showed decreased glutathione-dependent peroxidase activity and increased lipid peroxidation, both hallmarks of ferroptosis. Finally, the ferroptosis inhibitor SRS11-92 decreased the cell death associated with frataxin knockdown in healthy human fibroblasts. Taken together, these data suggest that ferroptosis inhibitors may have therapeutic potential in FRDA.